- Home
- BCV vs ALEC Comparison
BCV vs ALEC Comparison
Compare BCV & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCV
- ALEC
- Stock Information
- Founded
- BCV 1971
- ALEC 2013
- Country
- BCV United States
- ALEC United States
- Employees
- BCV N/A
- ALEC N/A
- Industry
- BCV Finance/Investors Services
- ALEC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BCV Finance
- ALEC Health Care
- Exchange
- BCV Nasdaq
- ALEC Nasdaq
- Market Cap
- BCV 110.8M
- ALEC 124.0M
- IPO Year
- BCV N/A
- ALEC 2019
- Fundamental
- Price
- BCV $19.21
- ALEC $1.63
- Analyst Decision
- BCV
- ALEC Buy
- Analyst Count
- BCV 0
- ALEC 7
- Target Price
- BCV N/A
- ALEC $4.70
- AVG Volume (30 Days)
- BCV 26.3K
- ALEC 535.0K
- Earning Date
- BCV 01-01-0001
- ALEC 08-06-2025
- Dividend Yield
- BCV 8.13%
- ALEC N/A
- EPS Growth
- BCV N/A
- ALEC N/A
- EPS
- BCV N/A
- ALEC N/A
- Revenue
- BCV N/A
- ALEC $88,339,000.00
- Revenue This Year
- BCV N/A
- ALEC N/A
- Revenue Next Year
- BCV N/A
- ALEC $319.82
- P/E Ratio
- BCV N/A
- ALEC N/A
- Revenue Growth
- BCV N/A
- ALEC N/A
- 52 Week Low
- BCV $14.09
- ALEC $0.87
- 52 Week High
- BCV $18.11
- ALEC $6.78
- Technical
- Relative Strength Index (RSI)
- BCV 69.55
- ALEC 57.56
- Support Level
- BCV $18.90
- ALEC $1.41
- Resistance Level
- BCV $19.14
- ALEC $1.75
- Average True Range (ATR)
- BCV 0.19
- ALEC 0.12
- MACD
- BCV 0.01
- ALEC 0.01
- Stochastic Oscillator
- BCV 98.89
- ALEC 67.90
About BCV Bancroft Fund Ltd.
Bancroft Fund Ltd is a diversified closed-end management company. It operates as a closed-ended equity mutual fund. The funds' main objective is to provide income and potential for capital appreciation. With the intent to achieve its objective, the company invests in convertible and equity securities. It invests across different industries such as Computer Software and Services, Energy and Utilities, Health Care among others.
About ALEC Alector Inc.
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.